dpp-4 inhibitors vs. glp-1 agonist Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology DPP-4 Inhibitors and the Quest
Description
Ozempic Face is the gaunt, aged facial appearance caused by rapid facial fat loss during GLP-1 therapy

After reviewing all clinical data for the medicine and consulting with regulators, Pfizer decided to halt research on it
It means we do not have the quality of evidence needed to make confident claims about efficacy
These findings appear to confirm the heart-healthy benefits of tirzepatide, which is already the most effective obesity drug of its kind on the market

It really is confusing even for a pharmacist, she said

Optimizing the use of glucagon-like peptide 1 receptor agonists in type 2 diabetes: executive summary
